Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Cancer Immunotherapy’

ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment

By on January 15, 2013

For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

The potential of this new treatment option was recognized at ASH 2012 by the award to Dr Bruce R. Blazar, MD and Carl H. June, MD of the Ernest Beutler Lecture and Prize for research that generated major translational advances in T-Cell Infusions.

ASH 2012 Carl June MD 1024x576 ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment

ASH 2012: Carl June, MD receives Ernest Beutler Prize

This is a preview of ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment. Read the full post

Leave a comment

Photoimmunotherapy may be a new way to deliver molecular-targeted cancer drugs

By on December 1, 2011

Photoimmunotherapy (PIT) that uses a near-infrared (NIR) dye conjugated to monoclonal antibodies (mABs) that target epidermal growth factor receptors (EGFR) is a new type of molecular-targeted cancer therapy that appears to offer considerable promise.

Research by Makoto Mitusnaga and colleagues from the Molecular Imaging Program at the National Cancer Institute (NCI) was published recently in Nature Medicine. This paper is well worth reading if you have an interest in this area.

The NCI researchers developed a:

“mAb-based photosensitizer that is activated by NIR light for targeted PIT only when bound to the target molecule on the cancer cellular membrane.”

This is a preview of Photoimmunotherapy may be a new way to deliver molecular-targeted cancer drugs. Read the full post

Leave a comment

A potential new Immunotherapy in Breast and Ovarian Cancer

By on November 9, 2011

There has been a lot of negative publicity around Dendreon and sipuleucel-T (Provenge) recently, and the lack of a clear mechanism of action remains a concern to many.

Irrespective of the company’s commercial performance, sipuleucel-T remains an FDA approved therapeutic cancer vaccine that provides a benefit to some patients.  It provided a proof-of-concept that immunotherapy can offer a survival advantage, albeit for a median of 4.1 months in asymptomatic advanced prostate cancer.

Dendreon is learning the hard way the failings in its commercial strategy, and no doubt these will be absorbed by others with other therapeutic vaccines in development.

This is a preview of A potential new Immunotherapy in Breast and Ovarian Cancer. Read the full post

Leave a comment